Marijuana Helps Crohn's Disease, Ulcerative Colitis
Crohn’s disease and ulcerative colitis, the two main types of inflammatory bowel disease (IBD), are a challenge to treat. Among the potential treatment options is marijuana, and several recent studies indicate that this unconventional option offers some significant benefits.
How we treat inflammatory bowel disease
The current treatment options for the more than 1.5 million Americans and millions more who suffer with inflammatory bowel disease include dietary measures (e.g., olive oil extract, vitamin D, probiotics) and a variety of drugs. These treatments attempt to alleviate the diarrhea, rectal bleeding, fever, weight loss and abdominal pain and cramps associated with the disease.
The more common treatments for IBD include anti-inflammatory drugs, such as sulfasalazine, corticosteroids (which have significant side effects and are only suitable for short-term use), mesalamine (e.g., Apriso, Dipentum, Lialda), immune system suppressors (e.g., azathioprine, cyclosporine, infliximab, adalimumab, certolizumab, methotrexate), which can have significant side effects, and antibiotics, which are of questionable benefit. Beyond these drugs are others that can address specific symptoms such as diarrhea, constipation, or pain, or address nutritional deficiencies (e.g., iron, calcium, vitamin B12). Surgery is a last resort.
Inflammatory bowel disease can be life-threatening and thus deserves focused attention. Ulcerative colitis typically affects only the large intestine (colon) and rectum and usually develops gradually over time. Crohn’s disease can occur anywhere along the intestinal tract and can infiltrate the tissues.
Studies of marijuana and IBD
A review of investigations into the use of cannabis for inflammatory bowel disease reveals that its use “in the clinical therapy has been strongly limited by their psychotropic effects.” The authors of this recent Italian study, however, point out that cannabidiol (a non-psychoactive and healthful ingredient in marijuana), “is a very promising compound” because it does not have any psychotropic effects, and that it is a “potential candidate for the development of a new class of anti-IBD drugs.”
A 2012 study published in Digestion noted that people who had had IBD for a long time responded favorably to marijuana, experiencing an increase in appetite, weight gain, better social functioning, improved ability to work, and an improvement in depression and pain after three months of treatment with inhaled cannabis. Earlier studies have also indicated positive effects.
For example, an Israeli study was the first to show that use of marijuana in people with Crohn’s disease could provide a positive result. Twenty-one of the 30 patients in the study experienced significantly improvement after using marijuana, and the need for drugs was significantly reduced as well.
In yet another study, Canadian researchers evaluated 100 people with ulcerative colitis and 191 with Crohn’s disease and their use of marijuana. The investigators found a significant level of marijuana use among people with ulcerative colitis and Crohn’s disease (about 50% in each group). People who had a history of surgery for IBD were more likely to use marijuana (60%) than were those who had not undergone surgery (32%).